X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
afatinib (1010) 1010
oncology (612) 612
index medicus (575) 575
humans (522) 522
gefitinib (460) 460
erlotinib (383) 383
chemotherapy (371) 371
open-label (360) 360
mutation (341) 341
lung neoplasms - drug therapy (321) 321
female (269) 269
lung cancer (252) 252
carcinoma, non-small-cell lung - drug therapy (246) 246
1st-line treatment (245) 245
adenocarcinoma (245) 245
cancer (226) 226
lung neoplasms - genetics (209) 209
male (208) 208
lung cancer, non-small cell (206) 206
egfr (200) 200
epidermal growth factor (192) 192
middle aged (189) 189
acquired-resistance (186) 186
aged (180) 180
cell lung-cancer (168) 168
non-small cell lung cancer (168) 168
protein kinase inhibitors - therapeutic use (166) 166
carcinoma, non-small-cell lung - genetics (161) 161
tyrosine kinase inhibitors (160) 160
quinazolines - therapeutic use (155) 155
antineoplastic agents - therapeutic use (154) 154
lung neoplasms - pathology (146) 146
tyrosine (142) 142
nsclc (140) 140
growth-factor receptor (139) 139
receptor, epidermal growth factor - genetics (138) 138
respiratory system (136) 136
tyrosine kinase inhibitor (134) 134
epidermal growth factor receptor (133) 133
care and treatment (124) 124
respiratory tract diseases (123) 123
erbb receptors - genetics (121) 121
treatment outcome (120) 120
adult (119) 119
egfr mutations (115) 115
pharmacology & pharmacy (114) 114
carcinoma, non-small-cell lung - pathology (113) 113
genetic aspects (112) 112
receptor, epidermal growth factor - antagonists & inhibitors (103) 103
analysis (102) 102
cancer therapies (102) 102
mutations (102) 102
phase-iii (102) 102
multicenter (100) 100
quinazolines - pharmacology (100) 100
tumors (100) 100
protein kinase inhibitors - pharmacology (99) 99
animals (98) 98
patients (97) 97
aged, 80 and over (95) 95
cell line, tumor (93) 93
antineoplastic agents - pharmacology (89) 89
metastasis (89) 89
quinazolines - administration & dosage (88) 88
therapy (88) 88
epidermal growth factor receptors (86) 86
kinases (85) 85
egfr mutation (83) 83
bibw 2992 (80) 80
research (80) 80
resistance (80) 80
trial (79) 79
adenocarcinoma - drug therapy (76) 76
non-small-cell lung cancer (76) 76
health aspects (75) 75
osimertinib (75) 75
antineoplastic combined chemotherapy protocols - therapeutic use (74) 74
drug therapy (74) 74
quinazolines - adverse effects (74) 74
disease-free survival (72) 72
non-small cell lung carcinoma (70) 70
clinical trials (68) 68
erbb receptors - antagonists & inhibitors (68) 68
phase-ii trial (68) 68
neoplasms. tumors. oncology. including cancer and carcinogens (66) 66
t790m (63) 63
hematology, oncology and palliative medicine (62) 62
erbb family blocker (61) 61
protein-tyrosine kinase (61) 61
antineoplastic agents - adverse effects (60) 60
adenocarcinoma of lung (58) 58
drug resistance, neoplasm (58) 58
medicine & public health (57) 57
original (56) 56
prognosis (56) 56
survival (56) 56
neoplasms (55) 55
lung-cancer (54) 54
cetuximab (53) 53
development and progression (53) 53
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1021) 1021
French (14) 14
Spanish (13) 13
German (6) 6
Chinese (5) 5
Korean (4) 4
Czech (3) 3
Hungarian (2) 2
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Roos, M
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 10/2017, Volume 40, Issue 10, pp. 639 - 639
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. 1897 - 1905
Introduction: Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor tyrosine kinase 2 (ERBB2) mutation; there is no approved targeted treatment for... 
Afatinib | ERBB2 mutation | NSCLC | BIBW 2992 | ADENOCARCINOMA | HER2 MUTATION | TRASTUZUMAB EMTANSINE | CHEMOTHERAPY | KINASE MUTATIONS | CELL LUNG-CANCER | PHASE-II TRIAL | THERAPY | CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 02/2019, Volume 164, pp. 181 - 186
A sensitive quantitative liquid chromatography-tandem mass spectrometry assay for afatinib in rat plasma was developed and validated using afatinib dimaleate... 
Stability | Determination | Liposomes | Afatinib | Pharmacokinetics | CHEMISTRY, ANALYTICAL | GEFITINIB | PHARMACOLOGY & PHARMACY | MASS-SPECTROMETRIC ASSAY | ERLOTINIB | Lung Neoplasms - drug therapy | Chromatography, High Pressure Liquid - methods | Injections, Intravenous | Chemical Fractionation - instrumentation | Male | Antineoplastic Agents - administration & dosage | Spectrometry, Mass, Electrospray Ionization - instrumentation | Sensitivity and Specificity | Drug Compounding | Models, Animal | Antineoplastic Agents - pharmacokinetics | Chemical Fractionation - methods | Tandem Mass Spectrometry - methods | Protein Kinase Inhibitors - pharmacokinetics | Tandem Mass Spectrometry - instrumentation | Afatinib - administration & dosage | Reproducibility of Results | Drug Stability | Rats | Chromatography, High Pressure Liquid - instrumentation | Rats, Sprague-Dawley | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Animals | Afatinib - pharmacokinetics | Spectrometry, Mass, Electrospray Ionization - methods | Antineoplastic Agents - blood | Protein Binding | Carcinoma, Non-Small-Cell Lung - drug therapy | Afatinib - blood | Tyrosine | Drugs | Drug delivery systems | Usage | Formic acid | Liquid chromatography | Precipitation (Meteorology) | Lung cancer, Non-small cell | Mass spectrometry | Vehicles | Protein binding
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2244 - 2250
PurposeARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naive patients with advanced non-small-cell lung... 
1ST-LINE TREATMENT | CONTROLLED-TRIAL | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | PHASE-3 TRIAL | OPEN-LABEL | AFATINIB | INHIBITOR | CHEMOTHERAPY | ERLOTINIB
Journal Article
Medicina Clinica, ISSN 0025-7753, 04/2016, Volume 146, Issue 146, pp. 19 - 24
After description of the importance of EGFR mutations in non-small cell lung cancer and confirmation that tyrosine-kinase inhibitors are more beneficial than... 
Afatinib | Second-line | EGFR
Journal Article
The Oncologist, ISSN 1083-7159, 01/2019, Volume 24, Issue 1, pp. 9 - 13
The large screening of exons 18 to 21 of the epidermal growth factor receptor (EGFR) gene may lead to the discovery of rare, atypical molecular alterations for... 
ACQUIRED-RESISTANCE | AFATINIB | ONCOLOGY | CANCER | PREDICTORS
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2018, Volume 82, Issue 6, pp. 1031 - 1038
The aim of this study was to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration using afatinib... 
EGFR mutation | Readministration | Medicine & Public Health | Afatinib | Non-small-cell lung cancer | Oncology | Cancer Research | T790M | EGFR-TKI | Pharmacology/Toxicology | 1ST-LINE TREATMENT | GEFITINIB | METAANALYSIS | ADENOCARCINOMA | OPEN-LABEL | PROSPECTIVE FEASIBILITY | CISPLATIN-BASED CHEMOTHERAPY | LOW-VOLUME HYDRATION | ONCOLOGY | PHARMACOLOGY & PHARMACY | JAPANESE PATIENTS | ERLOTINIB | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Afatinib - administration & dosage | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - enzymology | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Genes, erbB-1 | Antineoplastic Agents - adverse effects | Survival Analysis | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Afatinib - adverse effects | Afatinib - therapeutic use | Tyrosine | Chemotherapy | Epidermal growth factor | Oncology, Experimental | Clinical trials | Genetic aspects | Product development | Research | Lung cancer, Non-small cell | Cancer | Creatinine | Epidermal growth factor receptors | Toxicity | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Cytotoxicity | Disease control | Survival | Patients | c-Met protein | Confidence intervals | Lungs | Hypokalemia | Growth factors | Cytotoxic agents | Protein-tyrosine kinase | Tumors | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2018, Volume 82, Issue 5, pp. 757 - 766
Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy.As part of a phase I trial in patients with... 
Phase I | Medicine & Public Health | Afatinib | Paclitaxel | Carboplatin | Oncology | Cancer Research | Solid tumors | Pharmacology/Toxicology | BIBW 2992 | EGFR MUTATIONS | CHEMOTHERAPY | GEMCITABINE | CELL LUNG-CANCER | TRIAL | CISPLATIN | ONCOLOGY | PHARMACOLOGY & PHARMACY | ERBB FAMILY BLOCKER | ERLOTINIB | Afatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Male | Treatment Outcome | Carboplatin - pharmacokinetics | Paclitaxel - pharmacokinetics | Neoplasms - drug therapy | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Maximum Tolerated Dose | Afatinib - pharmacokinetics | Female | Afatinib - adverse effects | Neoplasms - pathology | Paclitaxel - administration & dosage | Antimitotic agents | Complications and side effects | Care and treatment | Chemotherapy | Diarrhea | Clinical trials | Antineoplastic agents | Tumors | Cancer | Renal function | Toxicity | Exanthema | Dehydration | Hemorrhage | Small intestine | Anticancer properties | Safety engineering | Safety management | Drug dosages | Neutropenia | Mucositis | ErbB protein | Fatigue | Pharmacology | Patients | Stomatitis | Antitumor activity | Sepsis | Pharmacokinetics | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6548 - 6555
Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations.... 
GROWTH-FACTOR RECEPTOR | MUTANTS | AFATINIB | ONCOLOGY | CANCER | AUY922
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 78, pp. 34765 - 34771
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their... 
Osimertinib | T790M | Afatinib | Rebiopsy | Bevacizumab
Journal Article
by Park, K
LANCET ONCOLOGY, ISSN 1470-2045, 07/2016, Volume 17, Issue 7, pp. E268 - E269
Journal Article
by Liu, YT and Li, Y and Ou, QX and Wu, X and Wang, XN and Shao, YW and Ying, JM
LUNG CANCER, ISSN 0169-5002, 04/2018, Volume 118, pp. 1 - 5
Objectives: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung... 
Resistance | Afatinib | NSCLC | ONCOLOGY | RESPIRATORY SYSTEM | Osimertinib | L718V | EGFR
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2012, Volume 2, Issue 10, pp. 922 - 933
EGFR-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs). The combination of EGFR-TKI afatinib and... 
lung cancer | EGFR tyrosine kinase inhibitors | afatinib | EGFR mutations | erlotinib | HER2 amplification | cetuximab | EGFR T790M | acquired resistance
Journal Article
Acta histochemica, ISSN 0065-1281, 09/2019, p. 151439
Afatinib, a second-generation tyrosine kinase inhibitor, was designed to bind covalently to and irreversibly inhibit active ErbB family receptors. The major... 
Journal Article
Bioanalysis, 09/2018, Volume 10, Issue 18, p. 1511
To support the therapeutic drug monitoring of afatinib (AFT), an ELISA was required. A hapten for AFT was prepared and linked to each of BSA and KLH proteins... 
Enzyme-Linked Immunosorbent Assay - methods | Animals | Rats | Afatinib - pharmacology | Drug Monitoring - methods | Afatinib - blood | Afatinib - therapeutic use
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, ISSN 1556-0864, 5/2017, Volume 12, Issue 5, pp. 884 - 889
Journal Article
ISSN 1758-1966, 07/2019
The current study evaluated the efficacy and tolerability of second-line afatinib in patients with mutation-positive ( m+) non-small-cell lung cancer (NSCLC)... 
afatinib | second line | EGFR
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.